---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-258568"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:13:57.032284+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics Q3 net loss $0.04/shr; cash $16.6M; CNSide commercial launch advances

## Summary
- Net loss of $4.4M ($0.04/shr) vs $2.9M ($0.37/shr) in Q3 2024; operating loss $4.5M.
- Cash and investments $16.6M (up from $6.9M on June 30, 2025 and $3.6M at Dec 31, 2024).
- First national coverage agreement with UnitedHealthcare for CNSide diagnostics, covering 51M+ lives.
- Houston lab received CLIA certification, enabling Medicare/Medicaid access and commercial payor coverage.
- Positive ReSPECT-LM Phase 1 results for REYOBIQ presented at SNO/ASCO; advance payment of $1.9M from CPRIT.

## SEC filing metadata
- accession: 0001193125-25-258568
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000119312525258568/0001193125-25-258568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000119312525258568/pstv-20251030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-258568
- JSON: https://secwatch.observer/filing/0001193125-25-258568.json
- Plain text: https://secwatch.observer/filing/0001193125-25-258568.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.